Summary:
The purpose of this study is to compare the efficacy and safety of switching treatment-resistant depression (TRD) participants from a prior antidepressant treatment (to which they have not responded) to either intranasal esketamine plus a new oral antidepressant or switching to a new oral antidepressant plus intranasal placebo.
Qualified Participants Must:
Be between 18 and 64 years of age (Adult)
Diagnosed with depression
Qualified Participants May Receive:
Study-related medical care and investigational drug at no cost and may be compensated for time and travel.